Skip to main content
Springer Nature Link
Log in

Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

Metastatic pheochromocytomas and paragangliomas (PPGLs) occur in about 5–26% of cases and are characterized by a heterogeneous prognosis. Metastases can be synchronous at the initial diagnosis, but they can occur also many years after surgery for the primary tumor. To date, the treatment of patients affected by metastatic PPGLs represents a clinical challenge because of the lack of guidelines.

Aim

The aim of this article is to review the available management options and their impact on the outcomes of patients with metastatic PPGLs.

Results

Generally, treatments are not curative. Surgery, when possible, can be used to reduce hormonal symptoms and cardiovascular morbidity. Chemotherapy plays a role in patients with high burden tumor and rapid disease progression. Tyrosine kinases inhibitors (TKIs) might be considered for their ability to block the angiogenesis and cell growth. Radiation therapy and interventional radiology techniques can help in the management of local metastases to control symptoms and avoid tumor progression. On the other hand, peptide receptor radionuclide therapy (PRRT), using 90Y or 177Lu-DOTATATE, could be a promising therapy. In addition, high specific 131I-MIBG was approved by the Food and Drug Administration (FDA) in the US for the treatment of patients affected by metastatic and unresectable 131I-MIBG positive PPGLs. Considering the different pathways involved in the pathogenesis of PPGLs, several target therapies have been proposed and are under evaluation in clinical trials.

Conclusions

The choice of the appropriate treatment should be based on multidisciplinary and personalized approach taking into account the rarity and the variability of these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine Society (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942. https://doi.org/10.1210/jc.2014-1498

    Article  CAS  PubMed  Google Scholar 

  2. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, Kerstens MN (2018) Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med 51:68–73. https://doi.org/10.1016/j.ejim.2018.01.015

    Article  PubMed  Google Scholar 

  3. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peçzkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466. https://doi.org/10.1056/NEJMoa020152

    Article  CAS  PubMed  Google Scholar 

  4. Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44(5):328–333. https://doi.org/10.1055/s-0031-1301302

    Article  CAS  PubMed  Google Scholar 

  5. Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14(2):108–119. https://doi.org/10.1038/nrc3648

    Article  CAS  PubMed  Google Scholar 

  6. Jochmanova I, Pacak K (2018) Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer 4(1):6–9. https://doi.org/10.1016/j.trecan.2017.11.001

    Article  CAS  PubMed  Google Scholar 

  7. Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M (2012) Updated and new perspectives on diagnosis, prognosis and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. https://doi.org/10.1155/2012/872713

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lam AK (2017) Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 28(3):213–227. https://doi.org/10.1007/s12022-017-9484-5

    Article  PubMed  Google Scholar 

  9. Tischler AS, de Krijger RR (2017) Phaeochromocytoma. In: Lloyd RV, Osamura RY, Kloppel G (eds) WHO classification of tumors of endocrine organs, 4th edn. IARC Press, Lyons, pp 183–189. ISBN 978-92-832-4493-6

    Google Scholar 

  10. Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11(3):423–436. https://doi.org/10.1677/erc.1.00829

    Article  CAS  PubMed  Google Scholar 

  11. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717–725. https://doi.org/10.1210/jc.2010-1946

    Article  CAS  PubMed  Google Scholar 

  12. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E (2013) Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 15(4):356–371. https://doi.org/10.1007/s11912-013-0320-x

    Article  PubMed  Google Scholar 

  13. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C (2014) Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111–R122. https://doi.org/10.1530/EJE-14-0113

    Article  CAS  PubMed  Google Scholar 

  14. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H (2007) Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92(4):1217–1225. https://doi.org/10.1210/jc.2006-1544

    Article  CAS  PubMed  Google Scholar 

  15. Angelousi A, Peppa M, Chrisoulidou A, Alexandraki K, Berthon A, Faucz FR, Kassi E, Kaltsas G (2019) Malignant pheochromocytomas/paragangliomas and ectopic hormonal secretion: a case series and review of the literature. Cancer (Basel). https://doi.org/10.3390/cancers11050724

    Article  Google Scholar 

  16. Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24(4):539–553. https://doi.org/10.1210/er.2002-0013

    Article  CAS  PubMed  Google Scholar 

  17. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Preibisz A, Timmers H, Plouin PF (2012) Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 44(5):385–389. https://doi.org/10.1055/s-0031-1301339

    Article  CAS  PubMed  Google Scholar 

  18. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Kriiger R, van Nederveen F, Nosé V (2009) Observer variation in the application of the pheochromocytoma of the adrenal glande scaled score. Am J Surg Pathol 33(4):599–608. https://doi.org/10.1097/PAS.0b013e318190d12e

    Article  PubMed  Google Scholar 

  19. Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR (1999) Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86:1583–1589

    Article  CAS  PubMed  Google Scholar 

  20. Nölting S, Grossman A, Pacak K (2019) Metastatic phaeochromocytoma: spinning towards more promising treatment options. Exp Clin Endocrinol Diabetes 127(2–03):117–128. https://doi.org/10.1055/a-0715-1888

    Article  CAS  PubMed  Google Scholar 

  21. Fuentes C, Menéndez E, Pineda J, Martínez De Esteban JP, Anda E, Goñi MJ, Bausch B, Neumann HP (2006) The malignant potential of a succinate dehydrogenase subunit B germline mutation. J Endocrinol Invest 29(4):350–352. https://doi.org/10.1007/bf03344107

    Article  CAS  PubMed  Google Scholar 

  22. Jimenez P, Tatsui C, Jessop A, Thosani S, Jimenez C (2017) Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress. Curr Oncol Rep 19(12):83. https://doi.org/10.1007/s11912-017-0643-0

    Article  CAS  PubMed  Google Scholar 

  23. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K (2012) Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48(11):1739–1749. https://doi.org/10.1016/j.ejca.2011.07.016

    Article  CAS  PubMed  Google Scholar 

  24. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P, Parmentier C (1992) Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15(9):631–642. https://doi.org/10.1007/BF03345807

    Article  CAS  PubMed  Google Scholar 

  25. Hamidi O (2019) Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr Opin Endocrinol Diabetes Obes 26(3):146–154. https://doi.org/10.1097/MED.0000000000000476

    Article  PubMed  Google Scholar 

  26. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Libé R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E, French Group of Endocrine and Adrenal Tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks) (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98(10):4006–4012. https://doi.org/10.1210/jc.2013-1907

    Article  CAS  PubMed  Google Scholar 

  27. Thosani S, Ayala-Ramirez M, Román-González A, Zhou S, Thosani N, Bisanz A, Jimenez C (2015) Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. Eur J Endocrinol 173(3):377–387. https://doi.org/10.1530/EJE-15-0456

    Article  CAS  PubMed  Google Scholar 

  28. Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, Que FG, Nagorney DM, Young WF, Thompson GB (2017) Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series. Ann Surg Oncol 24(6):1546–1550. https://doi.org/10.1245/s10434-016-5739-5

    Article  PubMed  Google Scholar 

  29. Jimenez C (2018) Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer. Front Endocrinol (Lausanne) 9:277. https://doi.org/10.3389/fendo.2018.00277

    Article  Google Scholar 

  30. Hamidi O, Young WF Jr, Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 102(9):3296–3305. https://doi.org/10.1210/jc.2017-00992

    Article  PubMed  PubMed Central  Google Scholar 

  31. Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C (2018) Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg 268(1):172–178. https://doi.org/10.1097/SLA.0000000000002195

    Article  PubMed  Google Scholar 

  32. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109(4):267–273. https://doi.org/10.7326/0003-4819-109-4-267

    Article  CAS  PubMed  Google Scholar 

  33. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 81(5):642–651. https://doi.org/10.1111/cen.12542

    Article  CAS  Google Scholar 

  34. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94(8):2850–2856. https://doi.org/10.1210/jc.2008-2697

    Article  CAS  PubMed  Google Scholar 

  35. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118(11):2804–2812. https://doi.org/10.1002/cncr.26577

    Article  CAS  PubMed  Google Scholar 

  36. Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M (2017) Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas/paragangliomas. Horm Cancer 8(2):108–118. https://doi.org/10.1007/s12672-017-0284-7

    Article  CAS  PubMed  Google Scholar 

  37. Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, Loaiza-Bonilla A, Fraker DL, Nathanson KL, Cohen DL (2017) SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer 24(8):L51–L55. https://doi.org/10.1530/ERC-17-0086

    Article  CAS  PubMed  Google Scholar 

  38. Jawed I, Velarde M, Därr R, Wolf KI, Adams K, Venkatesan AM, Balasubramaniam S, Poruchynsky MS, Reynolds JC, Pacak K, Fojo T (2018) Continued tumor reduction of metastatic pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy. Cell Mol Neurobiol 38(5):1099–1106. https://doi.org/10.1007/s10571-018-0579-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135(11):2711–2720. https://doi.org/10.1002/ijc.28913

    Article  CAS  PubMed  Google Scholar 

  40. Toledo R, Jimenez C (2018) Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factors inhibitors. F1000Research 30:7. https://doi.org/10.12688/f1000research.13995.1

    Article  CAS  Google Scholar 

  41. O’Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Onley HJ, Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ (2019) A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120(12):1113–1119. https://doi.org/10.1038/s41416-019-0474-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC (2017) Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine 57(2):220–225. https://doi.org/10.1007/s12020-017-1359-5

    Article  CAS  PubMed  Google Scholar 

  43. Emmanuel M, Pichun B, Edgerly M, Velarde M, Bates SE, Daerr R, Adams K, Pacak K, Fojo T (2015) Phase II clinical trial of axitinib in metastatic pheochromocytomas and paragangliomas (P/PG): preliminary results. J Clin Oncol 33:457. https://doi.org/10.1200/jco.2015.337_suppl.457

    Article  Google Scholar 

  44. Jimenez C, Fazeli S, Roman-Gonzalez A (2020) Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer. https://doi.org/10.1530/ERC-20-0043

    Article  PubMed  PubMed Central  Google Scholar 

  45. Gravel G, Leboulleux S, Tselikas L, Fassio F, Berraf M, Berdelou A, Ba B, Hescot S, Hadoux J, Schlumberger M, Al Ghuzlan A, Nguyen F, Faron M, de Baere T, Baudin E, Deschamps F (2018) Prevention of serious skeletal-related events by interventional techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine 59(3):547–554. https://doi.org/10.1007/s12020-017-1515-y

    Article  CAS  PubMed  Google Scholar 

  46. Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98(4):1492–1497. https://doi.org/10.1210/jc.2012-4231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, Hallemeier CL (2017) External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3(1):25–29. https://doi.org/10.1016/j.adro.2017.11.002

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, Bancos I, Young W Jr (2019) Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers (Basal) 11(2):195. https://doi.org/10.3390/cancers11020195

    Article  CAS  Google Scholar 

  49. Jimenez C, Erwin W, Chasen B (2019) Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers (Basal) 11(7):1018. https://doi.org/10.3390/cancers11071018

    Article  CAS  Google Scholar 

  50. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP (2014) (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 80(4):487–501. https://doi.org/10.1111/cen.12341

    Article  CAS  Google Scholar 

  51. Sze WC, Grossman AB, Goddard I, Amendra D, Shieh SC, Plowman PN, Drake WM, Akker SA, Druce MR (2013) Sequelae and survivorship in patients treated with (131)I-MIBG therapy. Br J Cancer 109(3):565–572. https://doi.org/10.1038/bjc.2013.365

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Mak IYF, Hayes AR, Khoo B, Grossman A (2019) Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive phaeochromocytoma and paraganglioma. Neuroendocrinology 109(4):287–298. https://doi.org/10.1159/000499497

    Article  CAS  PubMed  Google Scholar 

  53. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo VA, Mahmood S, Wong V, Jimenez C (2019) Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med 60(5):623–630. https://doi.org/10.2967/jnumed.118.217463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27(25):4162–4168. https://doi.org/10.1200/JCO.2008.21.3496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, Khoo B (2017) Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol 115(4):425–434. https://doi.org/10.1002/jso.24553

    Article  CAS  PubMed  Google Scholar 

  56. Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, Sharma S, Ochoa de Olza M, Varga A, Taylor M, Schellens JHM, Wu H, Sun H, Silva AP, Faris J, Mataraza J, Cameron S, Bauer TM (2020) A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 8(1):e000530. https://doi.org/10.1136/jitc-2020-000530

    Article  PubMed  PubMed Central  Google Scholar 

  57. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB (2009) Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41(9):697–702. https://doi.org/10.1055/s-0029-1220687

    Article  CAS  PubMed  Google Scholar 

  58. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ (2012) Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 118(24):6162–6170. https://doi.org/10.1002/cncr.27675

    Article  CAS  PubMed  Google Scholar 

  59. Giubellino A, Bullova P, Nölting S, Turkova H, Powers JF, Liu Q, Guichard S, Tischler AS, Grossman AB, Pacak K (2013) Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 154(2):646–655. https://doi.org/10.1210/en.2012-1854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Matro J, Giubellino A, Pacak K (2013) Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res 45(2):147–153. https://doi.org/10.1055/s-0032-1331211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406. https://doi.org/10.1200/JCO.2005.03.6046

    Article  CAS  PubMed  Google Scholar 

  62. Shindorf ML, Chaudhuri PK (2019) Single-agent thalidomide for treatment of malignant paraganglioma of the organ of zuckerkandl. Case Rep Med 2019:7185973. https://doi.org/10.1155/2019/7185973

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy

    G. De Filpo, M. Maggi, M. Mannelli & L. Canu

Authors
  1. G. De Filpo
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. M. Maggi
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. M. Mannelli
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. L. Canu
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to G. De Filpo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Filpo, G., Maggi, M., Mannelli, M. et al. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview. J Endocrinol Invest 44, 15–25 (2021). https://doi.org/10.1007/s40618-020-01344-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-020-01344-z

Keywords

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy